ARCHIVES

Ibrutinib Increases OS, PFS Versus Ofatumumab in Phase III

This article is from The Cancer Letter archive.

Vol. 37 No. 6 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

President Sppointed John Niederhuber NCI Director.

September 8, 2006

NCI Advisory Group, Other Cancer Meetings

June 2, 1989

Clinical Trials Approved By NCI During November Are Listed

December 27, 2002

FDA Advisors Recommend Approval Of Topotecan for Ovarian Cancer

April 26, 1996

NCI Plans To Expand CTSU Management Of Clinical Trials.

February 24, 2006

Zydelig Tablets Approved For Three Blood Cancers

July 25, 2014